endocrine Flashcards
(40 cards)
Type I DM
Autoimmune predisposition activated by environmental trigger
Tx: Insulin replacement mimicking physiologic insulin production and release; basal insulin supplemented with premeal short or ultra short acting.
Type II DM
Relative insulin deficiency due to either distended/distorted peripheral receptors or beta cell dysfunction (or both)
Tx: Oral therapy to sensitize insulin receptors (metformin or thiazolidinediones) and/or beta cell stimulation with sulfonylureas or non-sulfonylurea insulin sensitizers. Insulin is used only when 2 or more oral agents are maximized and glucose control still suboptimal. START WITH METFORMIN!
S/S of Type I DM
Weight loss, los of muscle mass, dehydration, pareshtesias, acetone breath, +/- mental status changes
S/S of Type II DM
Subtle: Vascular changes due to chronic hyperglycemia - nonhealing rashes, skin insult, hair loss in extremities. These changes take years to occur.
Diagnosis of DM
S/S of polyuria, polydipsia, unexplained wt. loss PLUS:
Fasting blood sugar (FBS) >126 or a random plasma glucose >200 on two separate occasions.
HbA1C >7% can also be diagnostic.
Management of DKA
Centers around isotonic fluid replacement and IV insulin at doses of 0.1u/kg/h and determining precipitating event.
Typical fluid deficit is 4-5 L upon presentation!
Most common complication of DM
Neuropathy
Somogyi effect
Nocturnal hypoglycemia develops, stimulating a surge of counterregulatory hormones that raise blood sugar, resulting in elevated early morning glucose levels.
Pt. is hypoglycemic at 3am and rebounds wtih elevated blood sugar at 7am.
Tx: reduce or omit the bedtime dose of insulin
Dawn phenomenon
Decreased sensitivity to insulin occurs nocturnally owing to the presence of growth hormone, which spikes at night. Blood sugar becomes progressively elevated throughout the night, resulting in elevated sugars at 7am.
Tx: Add or increase the bedtime dose of insulin
Type II oral agents that cause hypoglycemia
Sulfonylureas (glyburide, glipizide, etc) - insulin stimulator
Repaglinide (Prandin) - insulin stimulator
Nateglinide (Starlix) - insulin stimulator
Pramlintide (Symlin) - High risk for hypoglycemia Must be on strict carb intake per day.
Exenatide (Byetta) - may exacerbate hypoglycemia when administered with insulin or insulin stimulators Causes N/V
Type II oral agents that do NOT cause hypoglycemia
Biguanides (Metformin) - insulin sensitizer. Do NOT give if creat >1.5. Causes renal failure.
Alpha-glucosidase inhibitors - work in the gut to present the breakdown on glucose so it is not absorbed in your blood. Cause BAD GI side effects.
Thiazolidinediones - insulin sensitizer. Liver and heart SE.
Sitagliptin (Januvia) - people on this drug feel like they have an URI
Sulfonylureas
Insulin stimulators that can cause hypoglycemia
Include: Chlorpropamide, Glyburide, glucotrol, glypizide, glimepiride, tolazamide, tolbutamide
Less effective after >5 years of T2DM, older adults, or presence of severe hyperglycemia
Non-sulfonylureas (Meglitinides)
Insulin sitmulators with a more rapid onset. Can cause hypoglycemia.
Include: repaglinide (Prandin) and nateglinide (Starlix)
Take Medication 1-30 minutes prior to meal
Caution in hepatic or renal impairement
GLP-1 agonist
Exenatide (Byetta)
Can cause hypoglycemia if used with insulin or insulin stimulators.
Slows gastric emptying, leading to appetite suppression and weight loss
Major adverse effect: N/V, pancreatitis
Contraindicated in gastroparesis
Biguanides
Insulin sensitizers
Include: Metformin. Do NOT use of creat >1.5 or GFR
Alpha-glucosidase inhibitors
Take with first bite of meal
Work in the gut to block glucose metabolism. Can cause severe GI effects such as diarrhea, flatulence.
Include: Acarbose (Precose) and Miglitol (Glyset)
SE: diarrhea, increased flatus
Avoid in IBD and impaired renal function
Thiazolidinediones (TZD)
Insulin sensitizers that can cause heart and/or liver failure!
Include: rosiglitazone (Avandia) and pioglitazone (Actos)
Monitor ALT
Do not use with nitrates or insulin
Pioglitazone has increased risk of bladder cancer
Dipeptidyl peptidase-4 (DPP-4)
Sitagliptin (Januvia)
Inhibits idpeptidyl peptidase-4. Increases insulin synthesis/release, decreases glucagon levels.
Causes pts. to feel as though they have a URI with rhinitis, HA, etc.
Can develop pancreatitis
Hypothyroidism
Results from anti-thyroid antibodies (anti-TPO) blocking TSH receptors.
Have increased TSH and decreased T4.
Hashimotos is another name for this; most common thyroid disorder
Hyperthyroidism
Result of autoantibodies (thyroid stimulating immunoglobulins - TSI) acting like TSH and stimulating TSH receptors.
Have decreased TSH and increased T4. Will have very low or undetectable TSH levels.
Graves disease is another name for this.
Thyroid hormone
Sets the rate of gene transcription and metabolism. Excessess and deficiencies of this hormone will manifest in all body systems as a generalized “slow down” or “speed up”.
The most sensitive diagnostic marker of thyroid state
TSH level
Cortisol
A glucocorticoid that suppresses inflammation, maintains vascular tone, mobilizes glucose (and other fuel sources), promotes free water clearance
Aldosterone
A mineralocorticoid that increases renal reabsorption of sodium, subsequent water reabsorption
